Xueshan Qiu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xueshan Qiu has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
Jihong Chang
1 shared publicationLili Jiang
Department of Pathology, The First Affiliated Hospital and College of Basic Medical Sciences, China Medical University , Shenyang, Liaoning , China,1
1 shared publicationLimei Sun
Department of Pathology, the First Affiliated Hospital and College of Basic Medical Sciences, China Medical University, Shenyang, Liaoning, China
1 shared publicationQingfu Zhang
Department of Pathology, the First Affiliated Hospital and College of Basic Medical Sciences, China Medical University, Shenyang, Liaoning, China
1 shared publicationXiaoyu Sun
China Med Univ, Dept Pathol, Affiliated Hosp 1, 155 Nanjing North St, Shenyang 110001, Liaoning, Peoples R China
1 shared publication
Latest Publications
- 1 January 2021
- Vol. 13 (8) , 8653-8669
LncRNA TPTEP1 inhibited the proliferation and metastasis of non-small cell lung cancer cells by targeting miR-761/LATS2 axis
Objective: Non-small cell lung cancer (NSCLC) is highly metastatic that can lead to high fatality rate. This study aimed at investigating the possible role of LncRNA TPTEP1 (TPTEP1) in NSCLC progression. Methods: Cell proliferation was determined by MTT and colony formation assays. Transwell and scratch assays were adopted to assess cellular metastasis. RT-qPCR and western blot were used to detect TPTEP1 expression transcriptionally and translationally, respectively. The dual luciferase reporter assay and RNA immunoprecipitation assay were used to identify the specific target relationships. Results: Compared with the normal adjacent tissues, the expressions of TPTEP1 and LATS2 were significantly down-regulated in the NSCLC tissues, while the expression of miR-761 was significantly increased. Overexpression of TPTEP1 exhibited substantial antitumor effects on NSCLC, including inhibition of cell proliferation and metastasis, which was achieved by targeting miR-761 and subsequently attenuated the expression of LATS2. LATS2 was identified as a direct target of miR-761. Overexpression of miR-761 could significantly block the inhibitory effects of TPTEP1 on NSCLC, which clearly indicated that miR-761 played an oncogenic role in promoting proliferation and metastasis, while its downstream factor, LATS2, exerted opposite effects. Conclusion: The study showed that TPTEP1 played an inhibitory role in cancer progression of NSCLC cells by regulating miR-761/LATS2 cascade, thereby highlighting the potential therapeutic significance of TPTEP1/miR-761/LATS2 axis.
- 1 January 2021
- Vol. 13 (8) , 8653-8669
LncRNA TPTEP1 inhibited the proliferation and metastasis of non-small cell lung cancer cells by targeting miR-761/LATS2 axis
Objective: Non-small cell lung cancer (NSCLC) is highly metastatic that can lead to high fatality rate. This study aimed at investigating the possible role of LncRNA TPTEP1 (TPTEP1) in NSCLC progression. Methods: Cell proliferation was determined by MTT and colony formation assays. Transwell and scratch assays were adopted to assess cellular metastasis. RT-qPCR and western blot were used to detect TPTEP1 expression transcriptionally and translationally, respectively. The dual luciferase reporter assay and RNA immunoprecipitation assay were used to identify the specific target relationships. Results: Compared with the normal adjacent tissues, the expressions of TPTEP1 and LATS2 were significantly down-regulated in the NSCLC tissues, while the expression of miR-761 was significantly increased. Overexpression of TPTEP1 exhibited substantial antitumor effects on NSCLC, including inhibition of cell proliferation and metastasis, which was achieved by targeting miR-761 and subsequently attenuated the expression of LATS2. LATS2 was identified as a direct target of miR-761. Overexpression of miR-761 could significantly block the inhibitory effects of TPTEP1 on NSCLC, which clearly indicated that miR-761 played an oncogenic role in promoting proliferation and metastasis, while its downstream factor, LATS2, exerted opposite effects. Conclusion: The study showed that TPTEP1 played an inhibitory role in cancer progression of NSCLC cells by regulating miR-761/LATS2 cascade, thereby highlighting the potential therapeutic significance of TPTEP1/miR-761/LATS2 axis.
- 18 September 2013
- Published by Taylor & Francis in Cancer Investigation
- Vol. 31 (8) , 538-544
MicroRNA Hsa-miR-125a-3p Activates p53 and Induces Apoptosis in Lung Cancer Cells
The mature microRNA hsa-miR-125a-3p is derived from the 3′ end of pre-miR-125a. Here, we reported that hsa-miR-125a-3p suppressed proliferation and induced apoptosis in A549 cells. In addition, wild-type p53 mRNA and protein expression was increased by hsa-miR-125a-3p over-expression. Moreover, blocking wild-type p53 attenuated the effect of hsa-miR-125a-3p on apoptosis but could not restore completely. In p53-deficient cell line H1299, hsa-miR-125a-3p still induced apoptosis. Taken together, these data suggest that hsa-miR-125a-3p induces apoptosis not only via the p53 pathway in human lung cancer cells. These results provide new insight into the roles of the miR-125a family in lung cancer.
- 18 September 2013
- Published by Taylor & Francis in Cancer Investigation
- Vol. 31 (8) , 538-544
MicroRNA Hsa-miR-125a-3p Activates p53 and Induces Apoptosis in Lung Cancer Cells
The mature microRNA hsa-miR-125a-3p is derived from the 3′ end of pre-miR-125a. Here, we reported that hsa-miR-125a-3p suppressed proliferation and induced apoptosis in A549 cells. In addition, wild-type p53 mRNA and protein expression was increased by hsa-miR-125a-3p over-expression. Moreover, blocking wild-type p53 attenuated the effect of hsa-miR-125a-3p on apoptosis but could not restore completely. In p53-deficient cell line H1299, hsa-miR-125a-3p still induced apoptosis. Taken together, these data suggest that hsa-miR-125a-3p induces apoptosis not only via the p53 pathway in human lung cancer cells. These results provide new insight into the roles of the miR-125a family in lung cancer.